Clinical trials / NCT05427071
Recruiting

Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy

The use of neoadjuvant chemotherapy in breast cancer is expanding in the recent decade. Patients with good response to neoadjuvant chemotherapy could benefit from de-escalation of breast and axilla operation. However, breast tumor and involved axillary lymph node should be marked before the commencement of chemotherapy. This could facilitate subsequent operative planning and intraoperative assessment of disease response. This study aims to evaluate the feasibility of magnetic marker localization for non-palpable…

ClinicalTrials.gov IDNCT05427071
PhaseNA
Enrollment30
SponsorThe University of Hong Kong
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Breast Neoplasm, Chemotherapy Effect

About this study

The use of neoadjuvant chemotherapy in breast cancer is expanding in the recent decade. Patients with good response to neoadjuvant chemotherapy could benefit from de-escalation of breast and axilla operation. However, breast tumor and involved axillary lymph node should be marked before the commencement of chemotherapy. This could facilitate subsequent operative planning and intraoperative assessment of disease response. This study aims to evaluate the feasibility of magnetic marker localization for non-palpable breast cancer and targeted axillary dissection in patients with node-positive breast cancer following neoadjuvant therapy

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * All patients with cT1-3N1 invasive ductal carcinoma planned for neoadjuvant chemotherapy and/or target therapy * mentally competent to give informed consent * Agreed to proceed with curative operation after chemotherapy and tentatively keen for breast conservative surgery and targeted axillary dissection after neoadjuvant chemotherapy * Radiologically 1-3 ipsilateral axillary lymph node metastases confirmed by cytology or biopsy Exclusion Criteria: * Presence of distant metastasis, inflammatory breast cancers, multi-centric breast cancers * History of previous ipsilateral axillary surgery or irradiation * Hypersensitivity to dextran compounds or iron * Iron overload disease * Pregnant or lactating patients * Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder * Mentally incompetent patients

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.